<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257672</url>
  </required_header>
  <id_info>
    <org_study_id>FARM8E53XM</org_study_id>
    <secondary_id>2010-019787-36</secondary_id>
    <nct_id>NCT01257672</nct_id>
  </id_info>
  <brief_title>Symptomatic Treatment of Acute Gastroenteritis</brief_title>
  <official_title>Oral Ondansetron vs Domperidone for Symptomatic Treatment of Vomiting During Acute Gastroenteritis in Children: Multicentre Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Burlo Garofolo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agenzia Italiana del Farmaco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Burlo Garofolo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vomiting in children with acute gastroenteritis is a major factor of failure of oral
      rehydration therapy. Effective symptomatic treatment of vomiting would lead to an important
      reduction in the use of Intravenous Fluid Therapy. Available evidence on symptomatic
      treatment of vomiting shows the efficacy of the most recently registered molecule
      (ondansetron) but a proper evaluation of antiemetics drugs largely used in clinical practice,
      such as domperidone, is lacking.

      The aim of this multicentre, double-blind randomized controlled trial is to compare the
      efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children
      with acute gastroenteritis who have failed Oral Rehydration Therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vomiting in children with acute gastroenteritis (AG) is not only a direct cause of fluid loss
      but it is also a major factor of failure of oral rehydration therapy (ORT). Physicians who
      provide care to paediatric patients in the emergency department (ED) usually prescribe
      intravenous fluid therapy (IVT) for mild or moderate dehydration when vomiting is the major
      symptom. Thus, effective symptomatic treatment of vomiting would lead to an important
      reduction in the use of IVT and, consequently, of the duration of hospital stay and of
      frequency of hospital admission. Available evidence on symptomatic treatment of vomiting
      shows the efficacy of the most recently registered molecule (ondansetron) but a proper
      evaluation of antiemetics drugs largely used in clinical practice, such as domperidone, is
      lacking.

      The aim of this multicentre, double-blind randomized controlled trial conducted in paediatric
      Emergency Departments is to compare the efficacy of ondansetron and domperidone for the
      symptomatic treatment of vomiting in children with AG who have failed Oral Rehydration
      Therapy.

      The trial results would provide evidence on the efficacy of domperidone, which is largely
      used in clinical practice despite the lack of proper evaluation and a controversial safety
      profile, as compared to ondansetron, which is not yet authorized in Italy despite evidence
      supporting its efficacy in treating vomiting. The trial results would contribute to a
      reduction in the use of IVT and, consequently, in hospital admissions in children with AG.
      The design of this RCT, which closely reflect current clinical practice in EDs, will allow
      immediate transferability of results
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients needing nasogastric or intravenous rehydration after symptomatic oral treatment failure, defined as vomiting or fluid refusal after the second attempt of ORT.</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects needing hospital admission for the same illness;</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects needing observation stay for more than 6 hours for the same illness</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total emesis duration in the 3 allocation groups;</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of vomiting in the 3 treatment groups during the follow-up period</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects presenting adverse events</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">356</enrollment>
  <condition>Gastroenteritis</condition>
  <condition>Vomiting</condition>
  <condition>Acute Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ondansetron, syrup, 0,15 mg/Kg of body weight, 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>domperidon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>domperidone, syrup, 0,5 mg/Kg of body weight, one dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, syrup, one dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>ondansetron syrup (0,15 mg/Kg of body weight)</description>
    <arm_group_label>ondansetron</arm_group_label>
    <other_name>zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>domperidone syrup (0,5 mg/Kg of body weight)</description>
    <arm_group_label>domperidon</arm_group_label>
    <other_name>Motilium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age from 1 to 6 years;

          2. presumptive clinical diagnosis of acute gastroenteritis in patients with vomiting,
             with or without diarrhoea;

          3. more than three episodes of non-bilious, non-bloody vomiting within the previous 24
             hours;

        Exclusion Criteria:

          1. treatment with antiemetics or antidiarrhoic drugs in the 6 hours prior to access to
             ED;

          2. underlying chronic diseases (eg, malignancy, gastroesophageal reflux, migraine, renal
             failure, hypoalbuminemia, liver disease);

          3. severe dehydration: weight loss&gt;10% or standardized clinical dehydration score &gt;=18
             for children aged 12-24 months and &gt;=16 for older children;

          4. known hypersensitivity to ondansetron or domperidone;

          5. previous enrolment in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Marchetti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IRCCS Burlo Garofolo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maurizio Bonati, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mario Negri Institute for Pharmacological Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento di Pediatria, Ospedale Castelli</name>
      <address>
        <city>Verbania</city>
        <state>Novara</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Emergenza Pediatrica, Ospedale Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Emergenza Pediatrica, P.O. Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Emergenza Pediatrica, Ospedale Pediatrico A. Meyer</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Pediatria, Ospedale GB Morgagni</name>
      <address>
        <city>Forlì</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Emergenza Pediatrica, Istituto G. Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Pediatrica, Ospedale di Macerata</name>
      <address>
        <city>Macerata</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Pediatria, Azienda Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Emergenza Pediatrica, Azienda Ospedaliera - Università di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Pediatrica, Azienda Ospedaliera- Università di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Emergenza Pediatrica, Ospedale Pediatrico IRCCS Bambino Gesú</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Emergenza Pediatrica, Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Pediatria, Ospedale di Treviso</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Emergenza Pediatrica, Istituto per la l'Infanzia, IRCCS Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità di Terapia Intensiva Pediatrica, Ospedale Civile Maggiore</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Marchetti F, Maestro A, Rovere F, Zanon D, Arrighini A, Bertolani P, Biban P, Da Dalt L, Di Pietro P, Renna S, Guala A, Mannelli F, Pazzaglia A, Messi G, Perri F, Reale A, Urbino AF, Valletta E, Vitale A, Zangardi T, Tondelli MT, Clavenna A, Bonati M, Ronfani L. Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial. BMC Pediatr. 2011 Feb 10;11:15. doi: 10.1186/1471-2431-11-15.</citation>
    <PMID>21310051</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2010</study_first_submitted>
  <study_first_submitted_qc>December 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2010</study_first_posted>
  <last_update_submitted>April 17, 2014</last_update_submitted>
  <last_update_submitted_qc>April 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Burlo Garofolo</investigator_affiliation>
    <investigator_full_name>Ronfani Luca</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>acute gastroenteritis</keyword>
  <keyword>vomiting</keyword>
  <keyword>ondansetron</keyword>
  <keyword>domperidon</keyword>
  <keyword>symptomatic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

